Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
Is a
Allocation Type
Non-Randomized
0
Trial Collaborator
Participating Facility
Health Conditions in Trial
Intervention Model
Single Group Assignment
0
Interventional Trial Phase
Phase 1
0
Interventional Trial Purpose
Treatment
0
Last Updated
November 10, 2022
0
Masking Type
None (Open Label)
0
Primary Completion Date
2007
0
Trial Recruitment Size
12
0
Trial Sponsor
Clinical Trial Start Date
2005
0
Study Completion Date
2007
0
Clinical Trial Study Type
Interventional
0
NCT Number
Official Name
A Phase I, Open-Label Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin[NTN] to Assess the Safety and Tolerability of Intrastriatal Delivery to Subjects With Idiopathic Parkinson's Disease
0
Official Website
Find more entities like Safety of CERE-120 (AAV2-NTN) in Subjects With Idiopathic Parkinson's Disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.